Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT
| Autor: | Iqbal Siddique, Fuad Hasan, Jaber Al-Ali, Rosh Varghese |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Male
Specialties of internal medicine Pilot Projects Hepacivirus Gastroenterology Polyethylene Glycols chemistry.chemical_compound Pegylated interferon Pegylated Interferon education.field_of_study medicine.diagnostic_test biology Hepatitis C virus Genotype 4 Alanine Transaminase General Medicine Middle Aged Viral Load Recombinant Proteins Treatment Outcome RC581-951 RNA Viral Drug Therapy Combination Female medicine.drug Adult medicine.medical_specialty Combination therapy Adolescent Genotype Population Interferon alpha-2 Antiviral Agents Virus Internal medicine Biopsy Ribavirin medicine Humans education Adverse effect Normal transaminases Hepatology business.industry Interferon-alpha Hepatitis C Chronic chemistry Alanine transaminase Immunology biology.protein business Biomarkers |
| Zdroj: | Annals of Hepatology, Vol 11, Iss 2, Pp 186-193 (2012) |
| ISSN: | 1665-2681 |
| Popis: | Background. Approximately one-third of patients with chronic hepatitis C virus infection have persistently normal liver enzymes reflected by a normal serum alanine transaminase (ALT). Data with regards the efficacy and safety of treatment in patients chronically infected with Hepatitis C virus genotype 4 and normal serum ALT are limited. Aim. To evaluate the efficacy and safety of peginterferon alfa-2b plus ribavirin combination therapy in this population. Material and methods. Twenty-two patients with chronic hepatitis C virus genotype 4 infection were enrolled in an open-labeled, uncontrolled pilot study. All patients had biopsy proven chronic hepatitis and persistently normal serum ALT levels. Patients were treated with subcutaneous peginterferon alfa-2b at a dose of 1.5 μg/kg body weight once per week plus oral ribavirin (15 mg/kg/day) for 48 weeks. Patients were followed for 24 weeks post-treatment. Results. Sixteen patients out of twenty two completed the study (9 [40.9%] females, mean age 43.8 years). The ALT level were normal in all patients, with a mean of 38.6 U/L. Sustained viral response was achieved in 13 patients (59%), 4 patients (18.1%) were non-responders and 2 patients (9%) relapsed while 1 patient had a viral breakthrough during treatment. Two patients (9%) discontinued the treatment because of adverse events. Conclusions. Combination therapy of pegylated interferon-alpha2b and ribavirin is safe and resulted in a sustained viro-logical response in a significant number of patients with chronic Hepatitis C, genotype 4, and persistently normal serum ALT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|